

# Zhao Cui

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5189762/publications.pdf>

Version: 2024-02-01

107  
papers

2,742  
citations

159585

30  
h-index

223800

46  
g-index

108  
all docs

108  
docs citations

108  
times ranked

2299  
citing authors

#	ARTICLE	IF	CITATIONS
1	The genetic architecture of membranous nephropathy and its potential to improve non-invasive diagnosis. <i>Nature Communications</i> , 2020, 11, 1600.	12.8	120
2	Anti-Glomerular Basement Membrane Disease. <i>Medicine (United States)</i> , 2011, 90, 303-311.	1.0	113
3	Natural autoantibodies to myeloperoxidase, proteinase 3, and the glomerular basement membrane are present in normal individuals. <i>Kidney International</i> , 2010, 78, 590-597.	5.2	111
4	Prediction of Outcomes in Crescentic IgA Nephropathy in a Multicenter Cohort Study. <i>Journal of the American Society of Nephrology: JASN</i> , 2013, 24, 2118-2125.	6.1	85
5	Plasma soluble urokinase receptor levels are increased but do not distinguish primary from secondary focal segmental glomerulosclerosis. <i>Kidney International</i> , 2013, 84, 366-372.	5.2	83
6	MHC Class II Risk Alleles and Amino Acid Residues in Idiopathic Membranous Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1651-1664.	6.1	82
7	Advances in human anti-glomerular basement membrane disease. <i>Nature Reviews Nephrology</i> , 2011, 7, 697-705.	9.6	77
8	Antigen and Epitope Specificity of Anti-“Glomerular Basement Membrane Antibodies in Patients with Goodpasture Disease with or without Anti-Neutrophil Cytoplasmic Antibodies. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 1338-1343.	6.1	70
9	Novel ELISA for thrombospondin type 1 domain-containing 7A autoantibodies in membranous nephropathy. <i>Kidney International</i> , 2019, 95, 666-679.	5.2	68
10	Circulating Antibodies against Thrombospondin Type-I Domain-Containing 7A in Chinese Patients with Idiopathic Membranous Nephropathy. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2017, 12, 1642-1651.	4.5	66
11	Characteristics and Prognosis of Chinese Patients with Anti-Glomerular Basement Membrane Disease. <i>Nephron Clinical Practice</i> , 2005, 99, c49-c55.	2.3	63
12	Levels of epitope-specific autoantibodies correlate with renal damage in anti-GBM disease. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 1838-1844.	0.7	58
13	The immunoglobulin G subclass distribution of anti-GBM autoantibodies against rH $\pm$ 3(IV)NC1 is associated with disease severity. <i>Human Immunology</i> , 2009, 70, 425-429.	2.4	52
14	Anti-glomerular basement membrane autoantibodies against different target antigens are associated with disease severity. <i>Kidney International</i> , 2009, 76, 1108-1115.	5.2	51
15	Copy number variation of FCGR3A rather than FCGR3B and FCGR2B is associated with susceptibility to anti-GBM disease. <i>International Immunology</i> , 2010, 22, 45-51.	4.0	51
16	Clinical Features and Outcomes of Anti-“Glomerular Basement Membrane Disease in Older Patients. <i>American Journal of Kidney Diseases</i> , 2011, 57, 575-582.	1.9	51
17	Urinary soluble urokinase receptor levels are elevated and pathogenic in patients with primary focal segmental glomerulosclerosis. <i>BMC Medicine</i> , 2014, 12, 81.	5.5	49
18	The role of HLA-DRB1 alleles on susceptibility of Chinese patients with anti-GBM disease. <i>Clinical Immunology</i> , 2009, 133, 245-250.	3.2	47

#	ARTICLE	IF	CITATIONS
19	The clinical and immunological features of patients with combined anti-glomerular basement membrane disease and membranous nephropathy. <i>Kidney International</i> , 2014, 85, 945-952.	5.2	46
20	Clinical Significance of IgM and C3 Glomerular Deposition in Primary Focal Segmental Glomerulosclerosis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 1582-1589.	4.5	44
21	The frequency of ANCA-associated vasculitis in a national database of hospitalized patients in China. <i>Arthritis Research and Therapy</i> , 2018, 20, 226.	3.5	41
22	Comparison of characteristics of natural autoantibodies against myeloperoxidase and anti-myeloperoxidase autoantibodies from patients with microscopic polyangiitis. <i>Rheumatology</i> , 2011, 50, 1236-1243.	1.9	40
23	Complement Activation Contributes to the Injury and Outcome of Kidney in Human Anti-glomerular Basement Membrane Disease. <i>Journal of Clinical Immunology</i> , 2013, 33, 172-178.	3.8	40
24	Complement activation products in the circulation and urine of primary membranous nephropathy. <i>BMC Nephrology</i> , 2019, 20, 313.	1.8	38
25	Avidity of anti-glomerular basement membrane autoantibodies was associated with disease severity. <i>Clinical Immunology</i> , 2005, 116, 77-82.	3.2	37
26	The distribution of IgG subclass deposition on renal tissues from patients with anti-glomerular basement membrane disease. <i>BMC Immunology</i> , 2013, 14, 19.	2.2	37
27	The Alternative Pathway of Complement Activation May Be Involved in the Renal Damage of Human Anti-Glomerular Basement Membrane Disease. <i>PLoS ONE</i> , 2014, 9, e91250.	2.5	36
28	ANCA-associated vasculitis and anti-GBM disease: the experience in China. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 2062-2065.	0.7	35
29	Clinical implications of pathological features of primary membranous nephropathy. <i>BMC Nephrology</i> , 2018, 19, 215.	1.8	33
30	Complement C3a and C3a Receptor Activation Mediates Podocyte Injuries in the Mechanism of Primary Membranous Nephropathy. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 1742-1756.	6.1	33
31	Delayed severe pneumonia in mycophenolate mofetil-treated patients with IgA nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 2868-2872.	0.7	32
32	Rituximab for non-responsive idiopathic membranous nephropathy in a Chinese cohort. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 1558-1563.	0.7	32
33	Serum uromodulin and progression of kidney disease in patients with chronic kidney disease. <i>Journal of Translational Medicine</i> , 2018, 16, 316.	4.4	32
34	Performance evaluation of a novel chemiluminescence assay for detection of anti-GBM antibodies: an international multicenter study. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 243-252.	0.7	31
35	Concurrent Antiglomerular Basement Membrane Disease and Immune Complex Glomerulonephritis. <i>Renal Failure</i> , 2006, 28, 7-14.	2.1	30
36	Characteristics and Outcome of Chinese Patients with Both Antineutrophil Cytoplasmic Antibody and Antiglomerular Basement Membrane Antibodies. <i>Nephron Clinical Practice</i> , 2007, 107, c56-c62.	2.3	29

#	ARTICLE	IF	CITATIONS
37	Natural anti-GBM antibodies from normal human sera recognize Î±3(IV)NC1 restrictively and recognize the same epitopes as anti-GBM antibodies from patients with anti-GBM disease. <i>Clinical Immunology</i> , 2007, 124, 207-212.	3.2	28
38	FCGR2B gene polymorphism rather than FCGR2A, FCGR3A and FCGR3B is associated with anti-GBM disease in Chinese. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 97-101.	0.7	27
39	Antibodies against Linear Epitopes on the Goodpasture Autoantigen and Kidney Injury. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2012, 7, 926-933.	4.5	27
40	Primary glomerular nephropathy among hospitalized patients in a national database in China. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, 2173-2181.	0.7	26
41	The Complement C3a and C3a Receptor Pathway in Kidney Diseases. <i>Frontiers in Immunology</i> , 2020, 11, 1875.	4.8	26
42	The Immunopathological Spectrum of Crescentic Glomerulonephritis: A Survey of 106 Patients in a Single Chinese Center. <i>Nephron Clinical Practice</i> , 2010, 116, c65-c74.	2.3	24
43	The Genetic and Environmental Factors of Primary Membranous Nephropathy: An Overview from China. <i>Kidney Diseases (Basel, Switzerland)</i> , 2018, 4, 65-73.	2.5	24
44	Circulating anti-Î±glomerular basement membrane autoantibodies against Î±3(IV)NC1 undetectable by commercially available enzyme-linked immunosorbent assays. <i>Nephrology</i> , 2012, 17, 160-166.	1.6	22
45	T cell infiltration is associated with kidney injury in patients with anti-glomerular basement membrane disease. <i>Science China Life Sciences</i> , 2016, 59, 1282-1289.	4.9	22
46	HLA class II alleles differing by a single amino acid associate with clinical phenotype and outcome in patients with primary membranous nephropathy. <i>Kidney International</i> , 2018, 94, 974-982.	5.2	22
47	Association of Epitope Spreading of Antiglomerular Basement Membrane Antibodies and Kidney Injury. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 51-58.	4.5	21
48	Complement activation profile of patients with primary focal segmental glomerulosclerosis. <i>PLoS ONE</i> , 2020, 15, e0234934.	2.5	21
49	Influence of variable domain glycosylation on anti-neutrophil cytoplasmic autoantibodies and anti-glomerular basement membrane autoantibodies. <i>BMC Immunology</i> , 2012, 13, 10.	2.2	20
50	Plasma Exchange as an Adjunctive Therapy for Crescentic IgA Nephropathy. <i>American Journal of Nephrology</i> , 2016, 44, 141-149.	3.1	20
51	Antibodies to Î±5 chain of collagen IV are pathogenic in Goodpasture's disease. <i>Journal of Autoimmunity</i> , 2016, 70, 1-11.	6.5	19
52	Fever and prodromal infections in anti-Î±glomerular basement membrane disease. <i>Nephrology</i> , 2018, 23, 476-482.	1.6	19
53	Antibodies against M-Type Phospholipase A2 Receptor May Predict Treatment Response and Outcome in Membranous Nephropathy. <i>American Journal of Nephrology</i> , 2018, 48, 438-446.	3.1	19
54	The association of HLA-DQB1, -DQA1 and -DPB1 alleles with anti-glomerular basement membrane (GBM) disease in Chinese patients. <i>BMC Nephrology</i> , 2011, 12, 21.	1.8	18

#	ARTICLE	IF	CITATIONS
55	Autoantibodies against Linear Epitopes of Myeloperoxidase in Anti-“Glomerular Basement Membrane Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2016, 11, 568-575.	4.5	18
56	Clinical and prognostic significance of glomerular C1q deposits in primary MN. <i>Clinica Chimica Acta</i> , 2018, 485, 152-157.	1.1	18
57	Risk HLA class II alleles and amino acid residues in myeloperoxidase-“ANCA-associated vasculitis. <i>Kidney International</i> , 2019, 96, 1010-1019.	5.2	18
58	Clinical-Pathological Features and Outcome of Atypical Anti-glomerular Basement Membrane Disease in a Large Single Cohort. <i>Frontiers in Immunology</i> , 2020, 11, 2035.	4.8	18
59	Concurrent IgG4-related tubulointerstitial nephritis and IgG4 myeloperoxidase-anti-neutrophil cytoplasmic antibody positive crescentic glomerulonephritis. <i>Medicine (United States)</i> , 2017, 96, e6707.	1.0	16
60	Serum <scp>BAFF</scp> and <scp>APRIL</scp> might be associated with disease activity and kidney damage in patients with anti-“glomerular basement membrane disease. <i>Nephrology</i> , 2013, 18, 209-214.	1.6	14
61	Deglycosylation of myeloperoxidase uncovers its novel antigenicity. <i>Kidney International</i> , 2017, 91, 1410-1419.	5.2	14
62	The susceptible <scp>HLA</scp> class <scp>II</scp> alleles and their presenting epitope(s) in Goodpasture's disease. <i>Immunology</i> , 2017, 151, 395-404.	4.4	14
63	Plasma from patients with anti-glomerular basement membrane disease could recognize microbial peptides. <i>PLoS ONE</i> , 2017, 12, e0174553.	2.5	12
64	Soluble urokinase-type plasminogen activator receptor and incident end-stage renal disease in Chinese patients with chronic kidney disease. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 465-470.	0.7	12
65	Clinical and Immunologic Characteristics of Patients With ANCA-Associated Glomerulonephritis Combined With Membranous Nephropathy. <i>Medicine (United States)</i> , 2015, 94, e1472.	1.0	11
66	Clinical Features and Outcomes in Patients With Membranous Nephropathy and Crescent Formation. <i>Medicine (United States)</i> , 2015, 94, e2294.	1.0	11
67	Renal leukocyte chemotactic factor 2 (ALECT2)-associated amyloidosis in Chinese patients. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2020, 27, 134-141.	3.0	11
68	Membranous Nephropathy in Pregnancy. <i>American Journal of Nephrology</i> , 2020, 51, 304-317.	3.1	11
69	Rituximab Therapy for Primary Membranous Nephropathy in a Chinese Cohort. <i>Frontiers in Medicine</i> , 2021, 8, 663680.	2.6	11
70	Patients With Combined Membranous Nephropathy and Focal Segmental Glomerulosclerosis Have Comparable Clinical and Autoantibody Profiles With Primary Membranous Nephropathy. <i>Medicine (United States)</i> , 2016, 95, e3786.	1.0	10
71	The pathogenicity of T cell epitopes on human Goodpasture antigen and its critical amino acid motif. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 2117-2128.	3.6	10
72	Acute tubulointerstitial nephritis with germinal centers in antineutrophil cytoplasmic antibody-associated vasculitis. <i>Medicine (United States)</i> , 2019, 98, e18178.	1.0	10

#	ARTICLE	IF	CITATIONS
73	Laminin-521 is a Novel Target of Autoantibodies Associated with Lung Hemorrhage in Anti-GBM Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 1887-1897.	6.1	10
74	Influence of myeloperoxidase by anti-myeloperoxidase antibodies and its association with the disease activity in microscopic polyangiitis. <i>Rheumatology</i> , 2010, 49, 2068-2075.	1.9	9
75	Low-dose cyclosporine in treatment of membranous nephropathy with nephrotic syndrome: effectiveness and renal safety. <i>Renal Failure</i> , 2017, 39, 688-697.	2.1	9
76	The critical amino acids of a nephritogenic epitope on human Goodpasture autoantigen for binding to HLA-DRB1*1501. <i>Molecular Immunology</i> , 2017, 88, 1-9.	2.2	8
77	The Clinical and Immunologic Features of Patients With Combined Anti-GBM Disease and Castleman Disease. <i>American Journal of Kidney Diseases</i> , 2018, 71, 904-908.	1.9	8
78	Experimental Antiglomerular Basement Membrane GN Induced by a Peptide from Actinomyces. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1282-1295.	6.1	8
79	Predictors of Kidney Outcomes of Anti-Glomerular Basement Membrane Disease in a Large Chinese Cohort. <i>American Journal of Nephrology</i> , 2022, 53, 397-406.	3.1	8
80	Deglycosylation influences the oxidation activity and antigenicity of myeloperoxidase. <i>Nephrology</i> , 2018, 23, 46-52.	1.6	7
81	A Modified Peptide Derived from Goodpasture Autoantigen Arrested and Attenuated Kidney Injuries in a Rat Model of Anti-GBM Glomerulonephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 40-53.	6.1	7
82	Identification of Critical Residues of Linear B Cell Epitope on Goodpasture Autoantigen. <i>PLoS ONE</i> , 2015, 10, e0123277.	2.5	6
83	Delayed diagnosis of acromegaly in a patient with focal segmental Glomerulosclerosis: a rare case report and literature review. <i>BMC Nephrology</i> , 2019, 20, 435.	1.8	6
84	Epitope Mapping of Human $\lambda$ 3(IV)NC1-Induced Membranous Nephropathy in Mice. <i>American Journal of Nephrology</i> , 2020, 51, 99-107.	3.1	6
85	The clinical and immunological features of the post-extracorporeal shock wave lithotripsy anti-glomerular basement membrane disease. <i>Renal Failure</i> , 2021, 43, 149-155.	2.1	6
86	Glomerular C1q deposition and serum anti-C1q antibodies in anti-glomerular basement membrane disease. <i>BMC Immunology</i> , 2013, 14, 42.	2.2	5
87	Coexistence of Anti-Glomerular Basement Membrane Antibodies and Anti-Neutrophil Cytoplasmic Antibodies in a Child With Human Leukocyte Antigen Susceptibility and Detailed Antibody Description. <i>Medicine (United States)</i> , 2015, 94, e1179.	1.0	5
88	Anti-phospholipase A2 receptor antibodies directly induced podocyte damage <i>in vitro</i> . <i>Renal Failure</i> , 2022, 44, 304-313.	2.1	5
89	Rituximab for the treatment of refractory anti-glomerular basement membrane disease. <i>Renal Failure</i> , 2022, 44, 1124-1130.	2.1	5
90	Influence of myeloperoxidase-catalyzing reaction on the binding between myeloperoxidase and anti-myeloperoxidase antibodies. <i>Human Immunology</i> , 2012, 73, 364-369.	2.4	4

#	ARTICLE	IF	CITATIONS
91	Anti-glomerular basement membrane glomerulonephritis with thrombotic microangiopathy: a case report. <i>Immunologic Research</i> , 2017, 65, 769-773.	2.9	4
92	T cell responses to peptides of Goodpasture autoantigen in patients with anti-glomerular basement membrane disease. <i>Nephrology</i> , 2018, 23, 345-350.	1.6	4
93	Plasma exchange and rituximab treatments in primary membranous nephropathy combined with crescentic glomerulonephritis. <i>Medicine (United States)</i> , 2019, 98, e15303.	1.0	4
94	Effects of hydroxychloroquine on proteinuria in membranous nephropathy. <i>Journal of Nephrology</i> , 2021, , 1.	2.0	4
95	The prevalence and immunological features of anti-glomerular basement membrane antibody in patients with HIV. <i>BMC Nephrology</i> , 2020, 21, 429.	1.8	3
96	Antibodies against linear epitopes on Goodpasture autoantigen in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis. <i>Clinical Rheumatology</i> , 2017, 36, 2087-2094.	2.2	3
97	Epitope recognized by anti-glomerular basement membrane (GBM) antibody in a patient with repeated relapse of anti-GBM disease. <i>Experimental and Molecular Pathology</i> , 2019, 107, 165-170.	2.1	2
98	In-situ monitoring of membrane fouling migration and compression mechanism with improved Ultraviolet technique in membrane bioreactors. <i>Bioresource Technology</i> , 2022, 347, 126684.	9.6	2
99	In Reply to "The Influence of Age on the Clinical Features and Outcomes of Anti-glomerular Basement Membrane Disease". <i>American Journal of Kidney Diseases</i> , 2011, 58, 678-679.	1.9	1
100	<i>Nephrology in China</i> . , 2021, , 251-290.		1
101	Comparison of Ultrastructural Features Between Patients with Mercury-associated Membranous Nephropathy and Idiopathic Membranous Nephropathy. <i>American Journal of the Medical Sciences</i> , 2021, 361, 327-335.	1.1	1
102	A 16-year-old girl with sudden heart failure and nephrotic syndrome associated with Takayasu's arteritis. <i>Clinical Research in Cardiology</i> , 2022, 111, 221-226.	3.3	1
103	The Authors Reply:. <i>Kidney International</i> , 2014, 85, 1470-1471.	5.2	0
104	Complement activation profile of patients with primary focal segmental glomerulosclerosis. , 2020, 15, e0234934.		0
105	Complement activation profile of patients with primary focal segmental glomerulosclerosis. , 2020, 15, e0234934.		0
106	Complement activation profile of patients with primary focal segmental glomerulosclerosis. , 2020, 15, e0234934.		0
107	Complement activation profile of patients with primary focal segmental glomerulosclerosis. , 2020, 15, e0234934.		0